M
Maxcyte
MaxCyte, Inc specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes
About Maxcyte
MaxCyte operates in the biotechnology sector, specializing in scalable transfection systems that enhance cell engineering processes. The company serves a diverse range of clients including pharmaceutical companies, biotechnology firms, and academic institutions. MaxCyte's primary market is the life sciences industry, focusing on areas such as cell therapy, gene editing, and protein production. The business model revolves around selling its proprietary transfection systems and related services, which are designed to improve the efficiency, potency, and efficacy of cell-based therapies. Revenue is generated through the sale of these systems, as well as through long-term service agreements and licensing deals. MaxCyte's technology is particularly valuable for its ability to seamlessly scale from early research stages to commercial manufacturing, making it a critical tool for advancing therapeutic development.
Source: Dealroom company dataAt a glance
- Founded
- 1999
- Headquarters
- Gaithersburg, United States
- Listing
- IPO 2016
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Latest news
Press, funding announcements and product moves mentioning Maxcyte.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Intersouth Partners
Tall Oaks Capital Partners
Harbert Growth Partners
Series B and later4 investors entered at this stage
- HPHarbert Growth Partners
Sofinnova Partners- IPIntersouth Partners
- TPTall Oaks Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Maxcyte on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Maxcyte on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.